Allergy Immunotherapy

Global Allergy Immunotherapy Market to Reach US$4.7 Billion by 2030

The global market for Allergy Immunotherapy estimated at US$2.8 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 9.4% over the analysis period 2024-2030. Subcutaneous Immunotherapy (SCIT), one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$3.4 Billion by the end of the analysis period. Growth in the Sublingual Immunotherapy(SLIT) segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$780.1 Million While China is Forecast to Grow at 8.7% CAGR

The Allergy Immunotherapy market in the U.S. is estimated at US$780.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$719.3 Million by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 7.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.5% CAGR.

strong>Global Allergy Immunotherapy Market - Key Trends & Drivers Summarized

How Is Allergy Immunotherapy Transforming Allergy Treatment?

Allergy immunotherapy, also known as desensitization or hypo-sensitization, is a treatment designed to reduce the sensitivity of patients to allergens. Unlike traditional allergy treatments that focus on symptom management, immunotherapy addresses the root cause by gradually exposing patients to increasing doses of allergens, helping their immune system build tolerance. This approach has proven highly effective for conditions like allergic rhinitis, asthma, and insect allergies. The treatment can be administered via subcutaneous injections (SCIT) or sublingual tablets or drops (SLIT), offering long-term relief and reducing the need for medications.

What Innovations Are Driving Advances in Allergy Immunotherapy?

Recent advancements in allergy immunotherapy have improved its efficacy and convenience for patients. Novel immunotherapies, including shorter treatment durations and biologic-based therapies, are gaining traction. Biologics that target specific immune pathways, such as monoclonal antibodies, offer a promising approach to treating severe allergic reactions and chronic conditions like asthma. Additionally, research into personalized immunotherapy is growing, allowing treatments to be tailored based on individual patient profiles and their specific allergic triggers. These innovations are enhancing patient outcomes and broadening the scope of allergy treatment.

How Are Changing Environmental and Lifestyle Factors Impacting Allergy Prevalence?

The rising prevalence of allergies worldwide is largely attributed to environmental and lifestyle changes. Increased urbanization, pollution, and climate change have all contributed to the rise in allergic conditions, as people are exposed to more allergens such as pollen, dust, and mold. Additionally, changing dietary habits and modern living environments, which often lack early exposure to diverse microbes, have been linked to a higher incidence of allergies, particularly in children. These trends have heightened the need for more effective and long-lasting treatments like allergy immunotherapy.

What Factors Are Driving the Growth of the Allergy Immunotherapy Market?

The growth in the allergy immunotherapy market is driven by several factors, including the increasing prevalence of allergies, advancements in immunotherapy techniques, and rising awareness among patients and healthcare providers. The development of biologics and more personalized treatment approaches is expanding the range of patients who can benefit from immunotherapy. Additionally, the growing understanding of environmental and lifestyle factors contributing to allergies has prompted healthcare providers to adopt more proactive and long-term treatment strategies. As patient demand for more permanent allergy relief grows, immunotherapy is becoming an increasingly preferred treatment option.

SCOPE OF STUDY:

The report analyzes the Allergy Immunotherapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Allergy Type (Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, Other Allergy Types); Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Drug Stores, Online Pharmacy); Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy(SLIT))

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

• ALK-Abello A/S
• AllergoTek
• Allergy Therapeutics Plc
• American Academy of Cosmetic Surgery Hospital
• Ascent Ear Nose Throat Specialist Group Pte. Limited
• Best Life Medical Center, Inc.
• Desentum
• forTRA Health, Inc.
• HAL Allergy Group
• HOB Biotech Group Corp., Ltd.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more